Nom du produit:5-bromo-6-chloro-2,2-difluorobenzo[d][1,3]dioxole
IUPAC Name:5-bromo-6-chloro-2,2-difluoro-2H-1,3-benzodioxole
- CAS：869188-52-3
- Formule moléculaire：C7H2BrClF2O2
- Pureté：95%
- Numéro de catalogue：CM126179
- Poids moléculaire：271.44
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:869188-52-3
- Formule moléculaire:C7H2BrClF2O2
- Point de fusion:-
- Code SMILES:FC1(F)OC2=CC(Cl)=C(Br)C=C2O1
- Densité:
- Numéro de catalogue:CM126179
- Poids moléculaire:271.44
- Point d'ébullition:
- N° Mdl:MFCD09759045
- Stockage:Store at 2-8°C.
Category Infos
- Fluorinated Compounds
- Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.
Column Infos
- Fluorinated compounds
- Fluorinated compounds refers to organic or inorganic compounds containing fluorine.
- Zegocractin
- CalciMedica announces positive topline data from phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP). The trial met primary objective with statistically significant dose response. Calcium release–activated calcium (CRAC) channels are involved in activating T cells, and responsible for regulating calcium-dependent inflammatory pathways or tissue cell injury pathways. AP is a potentially life-threatening inflammatory disease of the pancreas featured by aberrant signaling of calcium.
CalciMedica’s Auxora is a potent and selective intravenous formulated CRAC channel inhibitor containing the active ingredient Zegocractin. It is being developed for the treatment of acute inflammatory and immunologic illnesses, including severe AP, AIPT, AKI, and severe acute respiratory diseases including AHRF, and ARDS.
Recherche 
+86 21 5895 0110 
